Market-Moving News for February 23rd

IPOWER, Inc. -0.88% Pre
Novo Nordisk A/S Sponsored ADR Class B +3.79% Pre
Vanda Pharmaceuticals Inc. -0.68% Pre

IPOWER, Inc.

IPW

1.13

1.11

-0.88%

-1.77% Pre

Novo Nordisk A/S Sponsored ADR Class B

NVO

40.81

41.06

+3.79%

+0.61% Pre

Vanda Pharmaceuticals Inc.

VNDA

7.27

7.27

-0.68%

0.00% Pre

VNDA: 54% | On Friday, The FDA Approved Vanda Pharmaceuticals' Bysanti (Milsaperidone) Tablets, A First Line Therapy For The Acute Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder And For Schizophrenia In Adults

 

NVO: -15% | Novo Nordisk's Headline Results From REDEFINE 4 Phase 3 Trial Of Cagrisema Shows 23% Weight Loss After 84 Weeks Of Treatment, Also Cagrisema 2.4/2.4 mg Did Not Meet The Primary Endpoint Of Showing Non-inferiority On Weight Loss Compared To Tirzepatide 15 mg At 84 Weeks

 

IPW: -16% | IPW stock has given up its prior gain. iPower shares were trading higher. The company reported Q2 financial results.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.